MedTrace Logo

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

NCT00981318 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2015-06-23

No results posted yet for this study

Summary

This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.

Conditions

  • HIV Infections
  • Acquired Immunodeficiency Syndrome

Interventions

DRUG

lopinavir/ritonavir plus maraviroc

lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Rodwick, Barry M., M.D.

    lead INDIV

Principal Investigators

  • Barry M. Rodwick, M. D. · Barry M. Rodwick, M. D.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981318 on ClinicalTrials.gov